

Growth acceleration

Maintained high profitability

February 22nd, 2024

Ben Page, CEO Dan Lévy, CFO



GROWTH ACCELERATION MAINTAINED HIGH PROFITABLITY



OPERATING PROFIT

13.1%

STRONG FINANCIAL POSITION

Leverage: $\times 0.3$






STRONG ORGANIC GROWTH IN ALL REGIONS IN Q4

In millions of euros	2023	Share	Organic growth Q4 2023	Organic growth 2023
EMEA	1,026.6	43%	11.2%	4.1%
Americas	956.4	40%	7.7%	1.7%
Asia-Pacific	406.8	17%	5.5%	3.5%
Total	2,389.8	100%	8.8%	3.0%



BETTER MOMENTUM IN TMT STRONG GROWTH IN MAIN SECTORS IN Q4



^{*} FY underlying organic growth without covid contracts. Organic growth with covid contracts: -2%



REVENUE BREAKDOWN BY AUDIENCE

In millions of euros	2023	Share	Organic growth Q4 2023	Organic growth 2023
Consumers ¹	1,126.8	47%	12.8%	7.1%
Clients and employees ²	530.0	22%	2.5%	0.1%
Citizens ³	351.2	15%	2.3%	-5.0%
Doctors and patients ⁴	381.8	16%	12.4%	3.6%
Total	2,389.8	100%	8.8%	3.0%

Breakdown of each Service Line by segment: breakdown of revenue by audience segment is non-financial data, likely to change over time depending on changes to the organization of Ipsos teams.

- 1. Brand Health Tracking, Creative Excellence, Innovation, Ipsos UU, Ipsos MMA, Market Strategy & Understanding, Observer (excl. public sector), Ipsos Synthesio, Strategy3
- 2. Automotive & Mobility Development, Audience Measurement, Customer Experience, Channel Performance (including Mystery Shopping and Shopper), Media development, ERM, Capabilities
- 3. Public Affairs, Corporate Reputation
- 4. Pharma (quantitative and qualitative)



HIGH PROFITABILITY MAINTAINED

In millions of euros	2023	2022	Variation
Revenue	2,389.8	2,405.3	-0.6%
Gross margin	1,612.8	1,594.1	1.2%
Gross margin / revenue	67.5%	66.3%	1.2 pt
Operating margin	312.4	314.7	-0.7%
Operating margin / revenue	13.1%	13.1%	0 pt
Other non-recurring income and expenses	(47.3)	3.7	
Finance costs	(13.3)	(13.2)	0.5%
Income tax	(72,9)	(72.8)	0.2%
Net profit attributable to owners of the parent	159.7	215.2	-25.8%
Adjusted net profit* attributable to owners of the parent	228.6	232.4	-1.6%

^{*} Adjusted net profit is calculated before non-cash items covered by IFRS 2 (share-based compensation), before amortization of acquisition-related intangible assets (customer relationships), before deferred tax liabilities related to goodwill for which amortization is deductible in some countries and before the impact net of tax of other non-recurring income and expenses. It is in particular adjusted for the provisions related to Russia.



7

CASH-FLOW STATEMENT

In millions of euros	December 31, 2023	December 31, 2022
Gross operating cashflow	412.9	401.9
Change in WCR	(65.2)	(14.4)
Income tax paid	(63.4)	(62.5)
Property, plant and equipment, intangible and financial assets	(61.6)	(57.3)
Net interest paid	(12.3)	(12.6)
Lease payments	(41.5)	(41.6)
ree cash flow	168.8	213.5
Acquisitions and financial investments	(47.9)	(9.5)
Purchase / Sale of shares	(85.5)	(29.9)
Net change in long-term borrowings	(57.5)	(31.0)
Dividends	(59.0)	(51.1)
ash position at end of period	277.9	385.7




STRONG FINANCIAL POSITION

In millions €	December 31, 2023	December 31, 2022
Equity	1,433	1,500
Net debt*	120	69
Net debt / EBITDA**	X 0.3	x 0.2

^{*}Bonds and bank loans net of cash

Gross debt: 396 m€ of which 76% at fixed rate



Liquidity: Close to **€500m** of undrawn credit lines with maturities > 1 year




9

^{**} Excluding IFRS 16 impact



EARLY SIGNS OF RECOVERY AMONG BIG TECH CLIENTS





2023 vs 2021: + 5% organic

2024: EXPECTED RECOVERY AND MODERATE GROWTH



AI IS DRIVING DEMAND AMONG BIG TECH CLIENTS

Understanding citizens

Google + Ipsos conducted one of the largest surveys on AI: "Our Life With AI"

Corporate reputation

What does a **responsible development** of Al look like?

Brand perception

How are different **brands perceived vs competitors** on Al solutions?

Innovation

Testing of embedded Al services: Bot, API, BtoB software, new devices



GOOD MOMENTUM IN PHARMA

Most headwinds are behind us: Post-pandemic reorganizations

Lower drug approvals in 2022

Organic growth acceleration: H1: -3% H2: +9%

Drivers: Advisory, Targeting / Segmentation solutions and Ad Campaigns

2024 Drivers

Drug approvals in 2023

Expansion of our offer

ESG Brand solutions Non-interventional studies Digital and Connected Health



GOOD GROWTH IN OUR NEW SERVICES

ORGANIC GROWTH +14%

SHARE OF TOTAL REVENUE 20%

Platforms

Ipsos.Digital, Ipsos Facto, Ipsos Synthesio, Simstore, Ipsos RISE...

ESG

Supporting our clients in their ESG journey (Diversity & Inclusion, Carbon footprint...)

Science & Data


Data analytics, AI, passive measurement...

Advisory

Data based advisory services



CHAMPIONING HUMAN AND ARTIFICIAL INTELLIGENCE





IPSOS FACTO: OUR GenAl PLATFORM

IPSOS' EMPLOYEES

Now available for IPSOS' CLIENTS

ACCESS TO A FULL SET OF TOOLS, INCLUDING DETAILED PROMPT LIBRARIES

Best Al language models on the market, continuously enriched by Ipsos data

SPEED AND PRODUCTIVITY
IN A SAFE ENVIRONMENT



AI / Genal POWERED CLIENT FACING SOLUTIONS

TRENDS, DISCOVERY & IDEATION

WEB LISTENING

Signals GenAl

brings impactful insights, based in category specific data instantly

ADVISORY

Assessment tool

Clients determine where they are on an Al Readiness model

QUALITATIVE SURVEYS

Al-Boosted Workshops

Ipsos expertise in workshopping with the power of GenAl to help clients with ideation

PRODUCT DEVELOPMENT

INNOVATION

InnoExplorer

GenAl enhanced innovation discovery and optimization for new ideas, concepts, packs and products

InnoPredict.Al

Concept validation

Product|Transfer

Identifies new markets for product launches

GO TO MARKET

17

CREATIVE EXCELLENCE

Creative Al (in the course of 2024)
Predicts KPIs for linear and social
platform video assets

UNDERSTANDING MARKET

Persona Bot (in the course of 2024)
Using GenAl to bring segments to life
and simulate responses to marketing
actions

BRAND & CONSUMER

BRAND HEALTH TRACKING

myBVC: Dashboard access to data and insights on our equity model

CORPORATE REPUTATION

RISE: Al-powered insight platform designed for modern brand, risk and reputation management

CUSTOMER EXPERIENCE

Experience Analytics Hub


Web application utilizing GenAl to enhance engagement with research data



© Ipsos | Full-Year Results 2023

IPSOS.DIGITAL: STRONG PROFITABLE GROWTH

REVENUE



x2 vs Group profitability

+31% vs 2022

In 2024:

Develop new solutions

Creative Spark will allow advertisers to test new type of media (Print & Outdoor, In-Store & Radio)


Expand existing offer

New features like Client Supplied Sample New sectors and geographies



STEPPING UP ON ACQUISITIONS: 9 DEALS SINCE 2022

PUBLIC AFFAIRS Big Village Australia Behaviour & Attitudes CBG Health Research I&O Research





Expected revenue in 2024: ~60M€



HIGH CLIENT SATISFACTION STAFF ENGAGEMENT MAINTAINED



CUSTOMER SATISFACTION

9/10



EMPLOYEE ENGAGEMENT

76%



WORLDWIDE RECOGNITION













VALUE CREATION FOR OUR SHAREHOLDERS

RECORD DIVIDENDS



SHARE BUY BACK PROGRAMME WITH THE INTENTION OF CANCELLATION

in 2023

50 m€

2.4%

of total shares

Continuing in 2024, based on the speed of our acquisitions



OUTLOOK 2024

ORGANIC GROWTH

Over 4%

OPERATING MARGIN

~13%



THANK YOU

Q&A session

Please find below the dial-in phone numbers:

France: +33(0)170 9187 04

UK: +44 121 281 8004

US: +17187058796

The password to access

the call is "**Ipsos**"

